CDKN2A and melanoma: For skin cancer, previous studies have assessed the benefits and harms of genetic testing for cyclin-dependent kinase inhibitor 2A (CDKN2A)—the major high-penetrance gene for melanoma [9,10]—among members of melanoma-prone families.